Antibodies to MOG in CSF only: pathological findings support the diagnostic value

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Budhram A, Kunchok AC, Flanagan EP (2020) Unilateral leptomeningeal enhancement in myelin oligodendrocyte glycoprotein immunoglobulin g-associated disease. JAMA Neurol 77:648–649. https://doi.org/10.1001/jamaneurol.2020.0001

    Article  PubMed  Google Scholar 

  2. 2.

    Di Pauli F, Höftberger R, Reindl M, Beer R, Rhomberg P, Schanda K et al (2015) Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol NeuroInflamm 2:e175. https://doi.org/10.1212/NXI.0000000000000175

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Höftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S et al (2020) The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 39:875–892. https://doi.org/10.1007/s00401-020-02132-y

    CAS  Article  Google Scholar 

  4. 4.

    Mariotto S, Gajofatto A, Batzu L, Delogu R, Pietro SG, Leoni S et al (2019) Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology 93:e1867–e1872. https://doi.org/10.1212/WNL.0000000000008479

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neuro 15:89–102. https://doi.org/10.1038/s41582-018-0112-x

    CAS  Article  Google Scholar 

  6. 6.

    Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S et al (2020) Myelin oligodendrocyte glycoprotein antibody-associated disease: An immunopathological study. Brain 143:1431–1446. https://doi.org/10.1093/brain/awaa102

    Article  PubMed  Google Scholar 

Download references

Funding

No funds, grants, or other support was received.

Author information

Affiliations

Authors

Contributions

Clinical data collection was performed by CS, BA, BS, BB, SM, OS, and MS. Pathological data analysis, interpretation, and description were performed by HR. Pathological preparation were performed by GG. Antibody analyses were performed by AD and SK. The conception and design of the study and interpretation of data were performed by RM, MR, FS, and MS. Interpretation and analyses of pathological data and antibody status were performed by CS, BS, FS, and MS. The first draft of the manuscript was written by CS and BA and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Sara Mariotto.

Ethics declarations

Conflict of interest

Markus Reindl was supported by research grants from Euroimmun and Roche and is supported by a research grant from the Austrian Science Fund (FWF projects P32699). The University Hospital and Medical University of Innsbruck (Austria; employer of Dr. Reindl) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Lübeck, Germany). Romain Marignier reports personal fees and non-financial support from Viela Bio, non-financial support from Merck, non-financial support from Biogen, personal fees and non-financial support from Roche, personal fees from UCB, outside the submitted work. S. Ferrari received a support for congress attendance by Shire, Euroimmun, and Merck. Sara Mariotto received support for attending scientific meetings by Merck and Euroimmun and received speaker honoraria from Biogen. The other authors have no relevant financial or non-financial interests to disclose.

Ethical standards

The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Carta, S., Höftberger, R., Bolzan, A. et al. Antibodies to MOG in CSF only: pathological findings support the diagnostic value. Acta Neuropathol 141, 801–804 (2021). https://doi.org/10.1007/s00401-021-02286-3

Download citation